Compare International Business Machines Corp (IBM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Twist Bioscience Corp — how do they compare? International Business Machines Corp trades at $226.95 (market cap $213.50B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: International Business Machines Corp is far larger — about 21.2× Twist Bioscience Corp's market cap, and International Business Machines Corp pays a 2.98% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Twist Bioscience Corp for 27 Days on average.
| IBM | TWST | |
|---|---|---|
Market Cap | $213.50B | $10.08B |
Volume | 8,908,687 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $329.23 | $205.00 |
52-Week Low | $205.77 | $25.45 |
Typical Hold Time | 88 Days | 27 Days |
Enterprise Value | $270.64B | $10.01B |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM stock trades at $227.13, up 3.0% today, showing resilience after recent volatility. The company reported strong Q4 2025 and Q1 2026 earnings beats but missed Q2 2026 expectations. Revenue growth accelerated to $67.54B in 2025 with net income margin improving to 15.52%. Technical indicators show bearish momentum with RSI at 71.56 suggesting overbought conditions, while analyst consensus remains positive with a $255.50 price target.
IBM's pivot to hybrid cloud and AI consulting shows promise with $5.5B generative AI bookings, though execution risks persist. The stock offers 12.5% upside to consensus target but faces headwinds from mainframe cyclicality and competitive pressure. Cash flow trends weakened in 2025 with negative net cash flow, requiring monitoring of capital allocation strategy.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
